T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.36% |
| 2 | Healthcare | 16.09% |
| 3 | Consumer Discretionary | 15.79% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Cameco
CCJ
$42.6B
| $378M | 0.03% |
17,326,319
-943,983
| -5% | -$22.8M |
|
402
Novanta
NOVT
$6.33B
| $377M | 0.03% |
2,139,728
-180,245
| -8% | -$30.1M |
|
403
Canadian Natural Resources
CNQ
$98.1B
| $375M | 0.03% |
18,132,980
-675,715
| -4% | -$13.7M |
|
404
East-West Bancorp
EWBC
$18.6B
| $374M | 0.03% |
4,747,860
+387,079
| +9% | +$31.1M |
|
405
Adaptive Biotechnologies
ADPT
$3.89B
| $373M | 0.03% |
13,286,713
+1,840,491
| +16% | +$56.4M |
|
406
Neurocrine Biosciences
NBIX
$15.3B
| $371M | 0.03% |
4,359,645
-104,640
| -2% | -$9.63M |
|
407
Aon
AON
$75.7B
| $370M | 0.03% |
1,232,373
-18,400
| -1% | -$5.52M |
|
408
Zentalis Pharmaceuticals
ZNTL
$297M
| $368M | 0.03% |
4,382,881
+652,456
| +17% | +$50.5M |
|
409
Rockwell Automation
ROK
$49.5B
| $367M | 0.03% |
1,051,042
-27,533
| -3% | -$9.12M |
|
410
Bankunited
BKU
$3.41B
| $360M | 0.03% |
8,505,864
-520,483
| -6% | -$21.8M |
|
411
Rexford Industrial Realty
REXR
$8.12B
| $359M | 0.03% |
4,424,153
+189,935
| +4% | +$13.2M |
|
412
Altria Group
MO
$109B
| $359M | 0.03% |
7,571,842
-887,707
| -10% | -$40.7M |
|
|
SUM
413
DELISTED
Summit Materials, Inc. Class A Common Stock
SUM
| $357M | 0.03% |
9,038,020
-17,845
| -0.2% | -$653K |
|
414
Wingstop
WING
$3.1B
| $357M | 0.03% |
2,064,219
+307,969
| +18% | +$51.6M |
|
415
Five Below
FIVE
$13.4B
| $357M | 0.03% |
1,723,270
+264,024
| +18% | +$51.9M |
|
416
Penumbra
PEN
$12.9B
| $356M | 0.03% |
1,238,709
+11,389
| +0.9% | +$3.01M |
|
417
Public Storage
PSA
$61.4B
| $356M | 0.03% |
949,741
-21,521
| -2% | -$7.19M |
|
418
Cognizant
CTSH
$26.7B
| $350M | 0.03% |
3,943,401
+1,117,658
| +40% | +$89.9M |
|
419
Leidos
LDOS
$17.9B
| $350M | 0.03% |
3,931,953
-151,357
| -4% | -$14.2M |
|
|
NBP
420
NovaBridge Biosciences American Depositary Shares
NBP
$220M
| $348M | 0.03% |
7,348,772
+2,463,847
| +50% | +$148M |
|
421
Manhattan Associates
MANH
$11.7B
| $345M | 0.03% |
2,215,807
-28,440
| -1% | -$4.62M |
|
422
DexCom
DXCM
$34.5B
| $344M | 0.03% |
2,564,432
+130,688
| +5% | +$18.8M |
|
423
Intel
INTC
$527B
| $344M | 0.03% |
6,671,501
-204,059
| -3% | -$10.4M |
|
424
Upwork
UPWK
$1.08B
| $343M | 0.03% |
10,043,245
-2,669,112
| -21% | -$118M |
|
|
PDCO
425
DELISTED
Patterson Companies, Inc.
PDCO
| $342M | 0.03% |
11,639,786
+17,766
| +0.2% | +$556K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.